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The study objective was to compare the effect of budesonide administered as a nebulized suspension as compared to 
a spray with a spacer in adult asthmatics. In a double-blind, double-dummy crossover study, 26 adult patients with 
moderately severe unstable asthma were randomized to three 4-week treatment periods with budesonide 0.8 mg 
b.i.d. administered by a pressurized metered-dose inhaler (pMD1) with spacer (Nebuhaler@) and budesonide 1 mg 
and 4mg b.i.d. administered by a Pari Inhalier Boy@ jet nebulizer. The nebulizer was activated only during 
inspiration. The total mass output was similar from the two devices but their fraction of small particles differed by 
a factor of 2 in favour of pMD1. Effect was evaluated from daily home measurements of peak expiratory flow (PEF), 
need of /&-agonist and symptom scores. Plasma cortisol and budesonide levels were measured in a subgroup of 10 
patients. 
A consistent trend showed the nebulizer treatment to be at least as efficient as the pMD1 plus spacer treatment. 
In actual fact, the apparent order of effect was: 4 mg nebulized suspension treatment 2 1 mg nebulized suspension 
treatment 2 0.8 mg pMD1 with spacer treatment. Plasma budesonide and plasma cortisol also exhibited dose-related 
levels independent of device. The adverse effects reported appeared to be related to the dose rather than delivery 
device. Accordingly, the effect was related to total mass output, rather than to the small particle fraction of the 
budesonide aerosol. 
These results attest to the efficiency of jet-nebulized budesonide suspension, and indicate nebulized budesonide to 
be equipotent to standard budesonide therapy delivered by pMD1 with Nebuhalera, provided nebulization is 
synchronized with inspiration and no loss of aerosol occurs during expiration. 
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Introduction 
Inhaled corticosteroids are becoming established drugs in 
the treatment of chronic asthma. The inhaled corticoster- 
oids attenuate bronchial inflammation and responsiveness 
to various trigger factors, improve the patient’s clinical 
status and reduce the number of asthma attacks. 
The inhaled corticosteroid budesonide has traditionally 
been administered using pressurized metered-dose inhalers 
(pMDI), often with spacers, or using a dry powder inhaler. 
Recently, a water suspension of budesonide has become 
available for jet nebulization. This inhalation form has been 
considered supplemental to the more common and simple 
inhaler devices, but may be of value in some infants, young 
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children (l-3) and older children or adults with particularly 
poor inhalation technique. 
A number of single-dose studies have compared the 
airway response to &-agonist delivered via a nebulizer and 
a pMD1, with (4-6) or without (7,8) a spacer. Despite the 
fact that, in most of these studies, the nominal dose of drug 
tested with the pMD1 was four- to eight-fold lower than 
that used with the nebulizer, airway response was shown to 
be comparable. From these single-dose studies, it has been 
suggested that to attain equipotency with a /&-agonist, a 
nominal dose ratio of between 4:l and 8:l is required when 
the drug is delivered from a nebulizer as compared with a 
pMD1 plus spacer (4,6,9). However, the inhaled mass of 
drug, i.e. the amount of drug inhaled by the patient from 
any of the devices used in these studies, was not defined. 
Therefore, it would seem to be difficult to draw any reliable 
conclusions from these studies regarding potency. Long- 
term crossover studies comparing bronchodilators admin- 
istered via pMDIs and nebulizers (10,ll) did not support 
the results of the single-dose studies. The crossover studies 
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demonstrated equivalent clinical efficacy with terbutaline 
sulphate (10) and ipratropium bromide (11) when equal 
nominal doses were administered by each device. Further 
in-depth investigation of both methods of drug delivery has 
demonstrated a similar dose-response with the two devices 
(12). The inhaled mass of drug was not determined in these 
studies. 
Isotope studies indicate that the lung dose may be 
comparable for the nebulizer and the pMDI (13,14) without 
spacer. It would appear, therefore, that data are equivocal, 
that the relatively large recommended nominal dose for 
nebulization requires re-evaluation and that a definition of 
the inhaled mass of drug is necessary in order to provide a 
sound basis for a device comparison. 
The present study was undertaken to assess the relative 
efficiency of budesonide administered from a pMDI 
with large-volume spacer and from a jet-nebulizer to 
adult patients with asthma, as measured by lung function, 
symptom response and requirement for additional p.r.n. 
medication. 
The study was designed as a three-way, double-blind, 
crossover study comparing the standard dose of budesonide 
pMD1 with the large-volume spacer (Nebuhale@!) 0.8 mg 
b.i.d. with 1 mg and 4 mg budesonide suspension b.i.d. 
administered by a Pari Inhalier Boy= jet nebulizer, each 
given for 4 weeks. In an attempt to standardize the inhaled 
mass of drug from the nebulizer, intermittent nebulization 
was applied which synchronized the nebulization with the 
inspiration. 
Patients and Methods 
Twenty-six patients (17 women) were selected for the study 
and started randomly on each treatment. Mean age was 45 
years (range 27-62 years), mean height 169 cm (range 154 
185 cm), mean weight 74 kg (range 51-118 kg) and mean 
FEV, 63% (range 36-93%) in percent of predicted normal. 
The patients had moderately severe asthma that was in- 
adequately controlled despite continuous treatment with a 
combination of inhaled steroids (041.0 mg daily) and b2- 
agonists. Inadequate control was defined as the persistence 
of symptoms and/or the presence of one or more measures 
of pulmonary function below 80% of the predicted value. 
Patients were excluded from entering the study if they had 
significant bronchopulmonary disease other than asthma, 
any other disease or disability likely to interfere with 
drug evaluation, or infection requiring antibiotic therapy. 
Patients who had been taking oral glucocorticosteroids dur- 
ing the month prior to the study were also excluded, as were 
those known to have a poor inhalation technique. 
Plasma budesonide and cortisol were measured in a 
subgroup of 10 patients. Mean age was 42 years (range 
31-57 years), mean height 169cm (range 158-183 cm), 
mean weight 72 kg (range 56-97 kg) and mean FEV, in 
percent of predicted of 65% (range 38-90%). The study 
was performed in accordance with the Guidelines of the 
Declaration of Helsinki, and was approved by the Ethics 
Committee of the Danish Board of Health. All patients 
gave informed consent prior to entry. 
STUDY DESIGN AND TREATMENT 
The trial was performed as a double-blind, double-dummy, 
crossover study with treatment periods of four weeks for 
each regime: 
(a) budesonide pMD1 with Nebuhaler@ 0.8 mg; 
(b) budesonide nebulized suspension 1 mg; and 
(c) budesonide nebulized suspension 4 mg. 
All treatments were administered b.i.d. To achieve blinding, 
all patients received a 4 ml suspension for nebulization 
accompanied by 4 puffs from a pMD1 with Nebuhalera, a 
750 ml spacer during each period. Every 4 weeks, the active 
ingredients of the regimens changed, although patient 
handling was the same. There was no washout period 
between treatments and no placebo-only period. Rescue 
medication of &-agonist was allowed as required. 
DELIVERY DEVICES 
Budesonide suspension was nebulized with a Pari Inhalier 
Boya jet nebulizer (Pari Werke GmbH, Germany) fitted 
with a mouthpiece and driven by a CR60 air compressor 
(Medic-Aid Ltd, U.K.) with a dynamic flow of 8 1 min ~ i. A 
4ml suspension of budesonide was used for nebulization. 
Patients were instructed: (a) to inhale tidally from the 
nebulizers; (b) to activate the nebulizer only during inspir- 
ation, using the finger-operated interrupt valve, to reduce 
the waste of the substance during expiration; and (c) to 
run the nebulizers to dryness but not to tap them. The 
budesonide pMD1 was fitted with a large-volume spacer 
(Nebuhaler@) for inhalation. Patients were instructed to 
inhale slowly from the spacer with tidal breathing for five 
cycles after each puff. 
The budesonide droplet size characteristics of the Pari 
Inhalier Boya jet nebulizer driven by a CR60 compressor 
were determined by connecting the jet nebulizer outlet to 
the glass inlet of a cascade impactor operating at 28 1 
min-’ . The nebulizers were run constantly until no aerosol 
was generated (approximately 4 min), and the amount of 
budesonide on the different impactor stages was determined 
using liquid chromatography. Budesonide suspension (2 ml, 
0.5 mg ml- ‘) was used for the tests. The ilz vitro tests 
included one run with each of two Pari Inhalier Boya jet 
nebulizers. 
The total output of budesonide from Pari Inhalier Boy@ 
jet nebulizer (eight individual devices) driven by a CR60 
compressor was further assessed in a fume cupboard, where 
the nebulizer was run to dryness. The nebulizer parts were 
washed after nebulization, the amount of budesonide 
washed out assayed by liquid chromatography and the 
measured amount of budesonide subtracted from the 
nebulizer charge of budesonide. In this set-up, no suction 
pump was connected to the nebulizer mouthpiece. 
The budesonide particle size characteristics from pMD1 
with Nebuhaler@ were determined in three Nebuhalera 
spacers which were primed with 15 doses of a budesonide 
pMD1 the day before the test. A 2OOpg budesonide puff 
was subsequently fired into Nebuhalera, and after 2 s, the 
dose was sampled for 10 s through an Anderson sampler 
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with a USP inlet and a flow of 28 1 min- ‘. This procedure 
was repeated five times. 
The budesonide aerosol output from the budesonide 
pMDI with Nebuhalera was defined by using five doses of 
2OOpg each, which were collected on filters placed at the 
mouthpiece of the NebuhalerB, and emptying the spacer 
through a constant flow immediately after actuation of the 
spray. 
ASSESSMENT 
Patients were asked to measure peak expiratory flow (PEF) 
at home using a mini-Wright Peak Flow Meter (Clement 
Clarke International Ltd, U.K.). The best of three measure- 
ments was recorded every morning and evening before 
aerosol treatment. Patients also kept a diary of coughing, 
wheezing, breathlessness, nocturnal asthma and normal 
activity (each recorded as yes or no). The number of puffs 
of concomitant &-agonist administered and the occurrence 
of adverse events were also recorded. Compliance was 
encouraged by telephoning each patient weekly. 
Clinic visits were made by all patients on entering the 
trial, and after each of the three treatment periods. Spirom- 
etry was performed during these visits. In addition to 
standard clinical assessments, plasma budesonide and cor- 
tisol levels were determined in a subgroup of 10 patients. 
These patients attended the clinic between 6.00 a.m. and 
7.00 a.m., and the morning budesonide inhalation was 
performed under supervision. Venous blood was taken for 
cortisol analysis before drug administration and 1 and 2 h 
afterwards. Additional samples were collected for plasma 
budesonide assay 9 min after the start of drug inhalation, 
on completion of nebulization and 10, 20, 50 and 110 min 
later. 
Plasma was analysed utilizing a high-performance 
liquid chromatography-radioimmunoassay (HPLC-RIA) 
method. The integrated plasma budesonide concentrations 
were utilized to generate a 2-h area under the curve (AUC). 
STATISTICAL ANALYSIS 
All treated patients were included in the analyses. Data 
from the last 2 weeks of each treatment phase were 
analysed; both diary card information and clinical 
determinants were assessed. 
The statistical analyses are based on an ANOVA model: 
Effect = patient + treatment + period + error. 
The three treatments were compared pairwise using this 
model. P values of ~0.05 were considered to be statistically 
significant and all tests were two-sided. P values of ~0.05 
was designated by * and P values of ~0.01 by **. 
Results 
Twenty-one of the 26 enrolled patients (8 1%) satisfactorily 
completed the trial protocol. One patient was excluded at 
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FIG. 1. Plasma cortisol vs the nominal dose of budeso- 
nide. Open bar, 0.8 mg x 2 pressurized metered-dose 
inhaler plus spacer; hatched bar, 1 mg x 2 nebulizer; solid 
bar, 4 mg x 2 nebulizer. 
the start of the study due to non-compliance. Two patients 
interrupted the study during the budesonide pMD1 regi- 
men; one because of pregnancy and the other as a conse- 
quence of a deterioration in asthma. Two other patients 
withdrew from the study during the budesonide nebuliz- 
ation (1 mg b.i.d.) treatment phase due to non-compliance 
and deteriorating asthma. 
IN VITRO MEASUREMENTS 
Thirty-three percent of the delivered dose from the 
nebulizer was contained in the fraction less than 4.7,um in 
diameter, and the droplet mass median aerodynamic diam- 
eter (MMAD) was estimated as 6.5pm. The total in vitro 
output was 58% (SD 5.3%) of the nebulizer charge, i.e. the 
dose of budesonide poured into the nebulizer. 
Sixty-nine percent (SD 5.3%) of the delivered doses from 
the pMD1 with Nebuhaler was contained in the fraction less 
than 4.7pm, and the particle MMAD was estimated as 
3.9 pm. The total output was 61% (SD 4.5%) of the nominal 
dose. 
CLINIC ASSESSMENTS 
Spirometry at the clinic revealed no statistically significant 
difference between the treatments. 
Plasma cortisol level determined prior to the morning 
administration of the drug regimens for the subgroup of 10 
patients exhibited a dose-related suppression (Fig. 1). The 
plasma cortisol level was significantly lower during the 
treatment with 4 mg budesonide suspension b.i.d. as com- 
pared to pMD1 0.X mg b.i.d. The 2-h AUC obtained from 
pooled plasma budesonide concentrations after treatment 
with the specified drug regimens showed a similar dose- 
effect relationship (Fig. 2). The mean AUC after admin- 
istration of 4 mg nebulized budesonide was significantly 
higher than that obtained after the 1 mg nebulized dose 
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FIG. 2. Plasma budesonide vs the nominal dose of 
budesonide. Open bar, 0.8 mg x 2 pressurized metered- 
dose inhaler plus spacer; hatched bar, 1 mg x 2 nebulizer; 
solid bar, 4 mg x 2 nebulizer. 
(P<O.Ol) and that obtained after the 0.8 mg pMD1 dosing 
(P<O.Ol). 
HOME ASSESSMENTS 
Symptom score, PEF and p.r.n. use of &agonist from the 
last 2 weeks of each treatment period are depicted as 
mean & SEM in Figures 3-5. The consistent trend in all effect 
variables demonstrates the nebulizer regimes to be as 
efficient or more efficient than the pMD1 plus spacer 
treatment. The high-dose regime was significantly more 
effective for PEF morning (P<O.Ol) and evening (P<O.Ol), 
use of &agonist (PcO.05) and for three out of five symp- 
toms (P<O.O5). The low-dose regime was significantly more 
effective for PEF evening (P<O.Ol) and for two of five 
symptoms (PcO.05). The 4 mg budesonide nebulizer 
suspension appeared to be equally or more effective than 
1 mg budesonide nebulizer suspension. However, the 
apparent difference between nebulizer dosages did not 
reach significance. Opposite trends were never observed. 
CONCOMITANT MEDICATION 
Five patients required concomitant anti-asthma medication 
whilst receiving 1 mg b.i.d. of budesonide by nebulization, 
as did four whilst receiving the 0.8 mg b.i.d. dosage by 
pMD1, and two whilst receiving the 4 mg b.i.d. nebulized 
dosage. A short course of prednisolone rescue was given 
three times during nebulization with 1 mg budesonide 
and once during nebulization at 4mg and with pMD1 at 
0.8 mg. 
One patient needed additional bronchodilators and 
another required nasal beclomethasone dipropionate 
(BDP) during treatment with the 1 mg nebulized dosage. 
BDP was taken by two patients during the pMD1 regimen. 
One patient used Becotide Rotacap@ (4 capsules b.i.d.) 
and the other used Beclofortea pMD1 4 puffs b.i.d. 
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FIG. 3. Symptoms scores vs the nominal dose of budeso- 
nide. Open bar, 0.X mg x 2 pressurized metered-dose 
inhaler plus spacer; hatched bar, 1 mg x 2 nebulizer; solid 
bar, 4 mg x 2 nebulizer. 
ADVERSE EVENTS 
Clinical signs of oral candidiasis occurred in five patients 
receiving 4 mg of nebulized budesonide compared with 
three patients receiving 1 mg and two patients receiving 
0.8 mg by pMD1. 
Discussion 
The results presented here suggest equipotency between 
budesonide pMD1 administered via a large-volume spacer 
and nebulized budesonide suspension administered syn- 
chronized with inspiration in adult asthmatics. The effect 
variables consistently showed the nebulizer regimes to be 
equal to or more efficient than the pMD1 and spacer 
treatment in this group of adult asthmatics. None of the 
outcome variables ever exhibited any trend in opposite 
direction. This attest to the efficiency of the budesonide 
suspension used for the jet nebulization. It should be 
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FIG. 4. Peak expiratory flow (PEF) morning and evening 
vs the nominal dose of budesonide. Open bar, 0.8 mg x 2 
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FIG. 5. Use of p.r.n. &-agonist vs the nominal dose of 
budesonide. Open bar, 0.8 mg x 2 pressurized metered- 
dose inhaler plus spacer; hatched bar, 1 mg x 2 nebulizer; 
solid bar, 4 mg x 2 nebulizer. 
emphasized that intermittent nebulization was used to 
assure optimal delivery of the aerosol in synchrony with the 
inhalations. During continuous nebulization, a loss of 
aerosol will occur during the exhalation reducing the 
potency of the nebulizer treatment by a fraction similar to 
the 1:E ratio. 
Dose-related effects from topical corticosteroids are sel- 
dom documented. The dose-relation found in the present 
study is probably related to the inclusion of patients with 
unstable asthma (15,16). These dose-related effects are also 
reflected in the plasma budesonide and cortisol levels. 
The systemically available dose of budesonide is mainly 
attributable to the lung deposition, from which budesonide 
is completely absorbed, whereas efficient first-pass metab- 
olism assures only marginal systemic bioavailability of the 
swallowed fraction of budesonide. Furthermore, the swal- 
lowed fraction of budesonide is probably not increased 
from nebulizer administration as compared to pMD1 with 
spacer administration (14). The dose-related plasma levels 
of budesonide and cortisol regardless of device, therefore, 
point to comparable lung deposition from the two delivery 
systems. 
In vitro measurements showed the two methods of drug 
delivery used in this study to be equivalent in terms of total 
drug output; the mean budesonide dose leaving the devices 
was approximately 60% of the nominal dose from either 
device. However, the MMAD differed between devices, 
from 3.9 ym with the pMD1 with spacer to 6.5 pm with the 
nebulizer. Accordingly, the pMD1 with spacer conveyed 
69% of the delivered dose in particles less than 4,7,um, 
whereas with the nebulizer, only 33% of the delivered dose 
had a particle size of less than 4.7,um. 
The clinical outcome indicate that a defined inhaled total 
mass of drug for the devices tested is a better predictor for 
the dose of drug delivered to the lungs of the patient than 
the estimated dose of fine particles. This was supported by 
the cortisol and ALJC budesonide in plasma. This is in 
contrast to the traditional concept, that only particles with 
a MMAD less than approx. 5,um are likely to reach the 
lower airway. However, the clinical data presented here 
suggest that a fraction of the dose that is contained in 
particles larger than 5 pm provides active anti-asthmatic 
corticosteroid therapy. Several explanation, though purely 
speculative, may explain this apparent paradox. 
LUNG TARGET AREA 
It seems likely that the target area in the lung varies 
between drugs, and the relevant target area for topical 
corticosteroids is not known. Central deposition with sub- 
sequent intrapulmonary redistribution may be sufficient, 
in which case particles larger than 5,~~rn may reach the 
relevant target. 
SYSTEMIC ACTIVITY 
The unique feature of topical corticosteroids is assumed to 
be a high local activity in relation to low systemic activity. 
However, the need for a systemic anti-asthmatic effect of 
topical corticosteroids may be underestimated. In this case, 
the comparable systemic bioavailability from either delivery 
system may explain the apparent clinical equipotency 
despite unequal lung distribution. 
DOSE DELIVERY BY PMDI 
The apparently favourable dose output from the pMDI 
with spacer system was measured 2 s after activation of the 
spray. The volume needed to empty an aerosol from a 
spacer is several-fold that of the spacer, due to exponential 
dilution of the aerosol by fresh air substituting the volume 
inhaled. The passive half-life of the aerosol in a plastic 
spacer is short due to the electrostatic attraction between 
plastic and particles (17). During tidal breathing, the delay 
in emptying the aerosol from the spacer may cause a loss of 
aerosol within the spacer, thus reducing the actual dose 
obtained. 
BUDESONIDE DISTRIBUTION 
The micronized budesonide particles do not distribute 
evenly throughout the aerosol droplets, thus the overall 
aerosol droplet profile may differ from the budesonide- 
containing particle profile. This is due to the fact that 
budesonide in suspension is available in particles of approx. 
3,um. Accordingly, the fine particle mass less than that is 
unlikely to contain any drug. 
IMPORTANCE OF PARTICLE SIZE 
The concept that only particles with MMAD less than 5 pm 
can provide therapeutic benefit in the lower airway is 
mainly based on studies of artificial monodisperse aerosols, 
which may not extrapolate to the polydisperse aerosols 
found in clinical practice. Lung deposition of nebulized 
budesonide appeared independent of droplet size within the 
range of 3-7 pm (18). Further, recent evidence questioned 
the importance of particle size in determining therapeutic 
response, at least with regard to the bronchodilator therapy 
(19-21). 
In any case, the present data illustrate that nebulization 
can efficiently deliver budesonide to the lungs. Nebulized 
regimens were well tolerated, and the occurrence of objec- 
tive adverse events and subjective discomfort was compar- 
able with that of the pMD1 regimen. The techniques may be 
comparable in clinical response in adults, provided inter- 
mittent inhalation of the nebulized suspension is used. 
Further research is, however, required before any recom- 
mendation or re-assessment of current dosing policy for 
either device may be advocated. 
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